FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk
  3. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  4. Q’Apel Medical, Inc.

    Q’Apel Medical marketed an uncleared modified HIPPO stroke aspiration device and had quality system violations, FDA says.

    High risk
  5. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  6. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  7. Techlem Medical Corporation

    Techlem Medical Corporation failed quality and unique device identifier requirements for wheeled stretchers, FDA says.

    Medium
  8. Sonesta Medical AB

    FDA warned Sonesta Medical AB that its radiographic and cystometric tables violated device quality system rules.

    Medium
  9. Centaur Pharmaceuticals Private Ltd.

    FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.

    High risk
  10. Nortec Quimica SA

    FDA warned Brazil's Nortec Quimica, an API maker, over deleted lab data and weak quality unit review of batches exported to the U.S.

    High risk
  11. Centrient Pharmaceuticals India Private Limited

    Centrient Pharmaceuticals India's API plant drew FDA CGMP violations, including weak records and unproven beta-lactam contamination testing.

    High risk
  12. Forcemech International LLC

    Forcemech International, a powered wheelchair relabeler in Pearland, Texas, lacked quality system procedures and UDI labeling, FDA says.

    Medium